Abstract:Background— Left ventricular assist device (LVAD) is being increasingly used in patients with end-stage dilated and ischemic cardiomyopathy. There have been no clinical trials addressing the use of LVAD therapy in patients with end-stage heart failure caused by restrictive (RCM) or hypertrophic cardiomyopathy (HCM). The purpose of this study was therefore to analyze the outcome of LVAD therapy in these patients. Methods and Results— Eighty-three patients received continuous axial flow LVAD (Heart mate II, Thoratec, Pleasanton, CA) from February 2007 to May 2010 at our institution. We analyzed the baseline characteristics and surgical and long-term impact of LVAD therapy in 8 patients with RCM or HCM and compared their outcomes with the 75 patients with dilated and ischemic cardiomyopathy. Compared with patients with ischemic or dilated cardiomyopathy, patients with RCM and HCM have significantly smaller left ventricular end-diastolic dimensions (52.5±6 mm versus 68.6±8 mm; P <0.0001) and increased thickness of septal (16 [12, 19] mm versus 10[8.5, 11] mm, P =0.0003) and higher left ventricular ejection fraction (21 [20, 36]% versus 17 [15, 22]%; P =0.0009). We found no difference in early mortality (12.5% versus 9.3%, P =0.57) or length of hospital stay (11 [8, 45] days versus 18.5 [12.2, 27.7] days; P =0.51) between the 2 groups. The right atrial pressure was higher (18 [15, 20] mm Hg versus 12 [9, 15] mm Hg, P =0.03), and pump flow was lower (4.3 [3.8, 4.5] L versus 5.2 [4.7, 5.5] L, P =0.001) after LVAD implantation in patients with RCM and HCM. Central venous catheter related infections were more common in patients with RCM and HCM (87.5% versus 44.5%, P =0.006). There was no difference in the total number of blood units transfused. Median (min, max) follow-up duration after LVAD implantation was 166 [1, 1044] days. The 1-year actuarial survival rate was not different between the 2 groups (87.5% [95% confidence interval, 52.9% to 97.8%] versus 73.2 [95% confidence interval, 60% to 85%]; P =0.77). Conclusions— Our preliminary data show that patients with end-stage heart failure caused by RCM or HCM may benefit from continuous axial flow LVAD therapy. This small study suggests that mortality is comparable with those patients who have dilated or ischemic cardiomyopathy, but right heart failure, prolonged inotropic use, and central venous catheter infections are more common in patients with RCM and HCM who were treated with LVAD. Because of the small numbers the differences should be interpreted cautiously, and prospective clinical trials would be required to recommend this therapy for these patients as bridge to transplantation or destination treatment.

Continuous flow left ventricular pump support and its effect on regional left ventricular wall stress: finite element analysis study

Hemodynamic effects of pulsatile unloading of left ventricular assist devices (LVAD) on intraventricular flow and ventricular stress.

Hemodynamic effects of various support modes of continuous flow LVADs on the cardiovascular system: A numerical study

Longitudinal analysis left ventricular chamber responses under durable LVAD support

Left Ventricular Hemodynamics with an Implanted Assist Device: An In Vitro Fluid Dynamics Study

Improving Hemodynamics of Cardiovascular System under a Novel Intraventricular Assist Device Support Via Modeling and Simulations

Computational characterization of flow and blood damage potential of the new maglev CH-VAD pump versus the HVAD and HeartMate II pumps

Computational Analysis of the Hemodynamic Characteristics under Interaction Influence of Β-Blocker and LVAD

Acute Hemodynamic Effects of Cardiac Resynchronization Therapy Versus Alternative Pacing Strategies in Patients With Left Ventricular Assist Devices

Myocardial Atrophy and Chronic Mechanical Unloading of the Failing Human Heart

Effects of Pulsatile Frequency of Left Ventricular Assist Device (LVAD) on Coronary Perfusion: A Numerical Simulation Study

Full-scale numerical simulation of hemodynamics based on left ventricular assist device

Left ventricular assist devices: A historical perspective at the intersection of medicine and engineering

Effects of left ventricular assist device support on biomarkers of cardiovascular stress, fibrosis, fluid homeostasis, inflammation, and renal injury

Patient-specific in silico prediction of outcomes of partial continuous-flow LVAD treatment in peripartum cardiomyopathy

[Study on direct ventricular assist loading mode based on a finite element method]

Exploring the Influence of Parametrized Pulsatility on Left Ventricular Washout under LVAD Support: A Computational Study Using Reduced-Order Models

Hemodynamic evaluation of a novel double lumen cannula for left ventricle assist device system

Left Ventricular Assist Device Therapy in Patients With Restrictive and Hypertrophic Cardiomyopathy

Enhancing the implantation of mechanical circulatory support devices using computational simulations

Effects of an intra-ventricular assist device on the stroke volume of failing ventricle: Analysis of a mock circulatory system